Option chain shows key data for Near Intelligence Inc Warrants (06/01/2025)'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Near Intelligence Inc Warrants (06/01/2025).

Near Intelligence Inc Warrants (06/01/2025) (OTC:NIRWQ) Stock, Option Chain

Near Intelligence Inc Warrants (06/01/2025)

WIIM

OKYO

OKYO Pharma shares are trading higher after the company announced it received $1.4 million in non-dilute funding.

Barclays analyst Matt Miksic maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and raises the price target from $20 to $21.

News

Price Target

Analyst Ratings

ATEC

Barclays Maintains Overweight on Alphatec Holdings, Raises Price Target to $21

Roth MKM analyst Rohit Kulkarni downgrades Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Buy to Neutral and raises the price target from $116 to $195.

Downgrades

RDDT

Roth MKM Downgrades Reddit to Neutral, Raises Price Target to $195

VINC

Vincerx Pharma shares are trading lower after the company announced it may offer and sell $30 million worth of common stock.

<a href="https://www.globenewswire.com/Tracker?data=QXq3KhPK_8AZgZP0kL1zm4OuPOBpEPdgK_fp2s7wK5bnwXPy3dRd5xP7xTL19DpM477m4sv30hFbPEa6vL3ajvbyFFCBQDbji-UXrcFNXR8=">KULR Technology Group, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) (the "Company" or "KULR"), a global leader in carbon-based thermal management and battery safety solutions, has announced an innovative collaboration with the prestigious Scripps Research Institute's Baran Lab. Together, the teams have developed a groundbreaking pyrolytic carbon (PC) electrode material, poised to transform synthetic organic electrochemistry.
The jointly developed electrode is a low-cost, robust, and versatile alternative to traditional amorphous carbon materials such as reticulated vitreous carbon (RVC) and glassy carbon (GC). With unparalleled mechanical strength and reactivity comparable to RVC and GC, this novel PC material overcomes the limitations of cost and scalability that have historically constrained large-scale synthetic organic applications.
Key Advancements:
<ul>
<li>Affordable and Scalable: The pyrolytic carbon electrodes are produced using a proprietary chemical vapor deposition (CVD) process, significantly reducing manufacturing costs and making large-scale synthesis feasible.</li>
<li>Versatile Applications: The material performs exceptionally well across a range of electrochemical reactions, including rapid alternating polarity (rAP) Kolbe couplings, which are essential for high-value chemical production.</li>
<li>Durability and Recyclability: Unlike fragile RVC electrodes, PC electrodes are mechanically robust, enabling simple cleaning and reusability without degradation.</li>
</ul>

KULR

KULR Technology Group And Scripps Research Institute's Baran Lab Develop Cost-Effective Pyrolytic Carbon Electrode For Synthetic Organic Electrochemistry; Enhances Scalability, Versatility In Reactions, And Durability With Proprietary Chemical Vapor Deposition Process

Barclays analyst Kannan Venkateshwar downgrades Rogers Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) from Overweight to Equal-Weight and lowers the price target from C$63 to C$39.

TSX:RCI

TSX:RCI/B

Barclays Downgrades Rogers Communications to Equal-Weight, Lowers Price Target to C$39

Xilio Therapeutics shares are trading lower after the company reported initial data from its ongoing Phase 2 clinical trial evaluating vilastobart in combination with atezolizumab.

Goldman Sachs CEO Solomon Says I Don't Think Bitcoin Is A Threat To The U.S. Dollar

Trading Ideas

RZLV

Rezolve AI Shares Trading Higher; Co Issues Press Release Celebrating Stargate AI Initiative

HUSA

Houston American Energy shares are trading lower after the company announced a $4.42 million registered direct offering.

GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) will release its fourth-quarter financial results before the <a href="https://www.benzinga.com/quote/GE/earnings">opening bell on Thursday, Jan. 23</a>.
Analysts expect the Ohio-based company to report quarterly earnings at $1.04 per share, up from $1.03 per share in the year-ago period. GE Aerospace projects quarterly revenue of $9.47 billion, compared to $19.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 2, Deutsche Bank analyst Scott Deuschle maintained GE Aero with a Buy rating and lowered the price target from $235 to $228.
With the recent buzz around GE Aerospace, some investors may be eyeing potential gains from the company's dividends. As of now, GE Aerospace offers an annual dividend yield of 0.60%, which is a quarterly dividend amount of 28 cents per share ($1.12 a year).
To figure out how to earn $500 monthly from GE Aerospace, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by GE Aerospace's $1.12 dividend: $6,000 / $1.12 = 3,000 shares.
So, an investor would need to own approximately $1,004,438 worth of GE Aerospace, or 5,357 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.12 = 1,071 shares, or $200,813 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
GE Price Action: Shares of GE Aerospace gained by 2.5% to close at $187.50 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

Markets

How To Earn $500 A Month From GE Aerospace Stock Ahead Of Q4 Earnings

USEG

U.S. Energy Corp shares are trading higher. The company announced a public offering of 4,236,000 shares.

Barclays analyst Kannan Venkateshwar downgrades BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) from Equal-Weight to Underweight and lowers the price target from C$41 to C$30.

TSX:BCE

Barclays Downgrades BCE to Underweight, Lowers Price Target to C$30

LSTA

Lisata Therapeutics shares are trading lower after the company announced preliminary cohort data from its Phase 2 Ascend trial.

HPAI

Helport AI Partners With LendSure To Boost Loan Officer Productivity, Reduce Overhead Costs, And Lower Mortgage Expenses For Borrowers; Aims For Industry-Wide Transformation Through AI Integration

HEPA

Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.

BLBX

Blackboxstocks shares are trading higher after the company announced a $250K securities purchase agreement and is anticipating a potential merger.

Offerings

U.S. Energy Corp. Prices 4,236,000 Share Offering At $2.65/Share

Goldman Sachs CEO Solomon Says Rebalancing Of Certain Trade Agreements Over Time Can Be Constructive For U.S. Growth; I Think It's Hard To Dispute The Fact That Equity Multiples Are High

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue
OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Lp7r-Zko8_STxa2-SCTwWJh1YHEsWboXq5jsxeXHg-SqFEWiqVGMujh5tpqwQxZY5yu2XZuEKP-kqNipNfkoTz27dgqboQ8x6ThGGR7FHqU=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today offered commentary on a new article in the Journal of General Internal Medicine linking COVID-19 to increased risk of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ("ME/CFS").
The article, titled "<a href="https://www.globenewswire.com/Tracker?data=Fpq1FisR8Jo1G0UQe1w_Xfyq974COCvW4D_zDbhx6_5A0ny4E4Th5BAnjftaot2-CBsrvkrvPy4vLK9ZH3_XPf6BEtDKxILgAsWUrhbxQtb9G1eL_d0RHXTAtQyiV1dDgtvGWyL_CXYP8dEKM0sl_e5o6kWll7Ml4HPjKmEAZbaCJFKGMw0km6H3jqqnBplMJoqzXHwWq6c0FZBZ48Kk9SNpfqFRHl4ud2cVHkg-JSiJXXFaA4j39hkqvOp3hWvEPVi255ewcc5zYELBzc3yQw==">Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study</a>," found that among study participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates. The article's lead author, Suzanne D. Vernon, PhD, emphasized the following highlights in an <a href="https://www.globenewswire.com/Tracker?data=IFH4V9qJpmVon0e6WwLx9F-9dJ-PXSwcqmf6AWGKFGpioE4g2C0XT-vTSog6ur1kSKv3Tqel3TlMk2tZv_ZxO8FrpaAyqaJe6oAT9qQmwriMCO59gtO7iuWk983XNcr_9yKUh6iDzSoInm9YYBi9MQ==">accompanying analysis</a> posted to the Bateman Horne center website:
<ul>
<li>Of the 4,515 participants who enrolled within 30 days of contracting COVID-19, 73 developed ME/CFS at least six months post-infection.</li>
<li>In total, 531 participants met ME/CFS criteria, translating to a prevalence of 4.5% among those infected—nearly eight times higher than uninfected participants.</li>
<li>This prevalence is five times higher than pre-pandemic estimates and underscores the severe and lasting impact of COVID-19 on public health.
<ul>
<li>90% of these post-COVID-19 ME/CFS cases clustered with the most symptomatic and severe cases of Long COVID, highlighting the overlap between these two conditions.</li>
</ul>
</li>
</ul>

Biotech

General

AIM ImmunoTech Announces Commentary On Study Linking COVID-19 To Increased ME/CFS Risk; Incidence 15 Times Higher Than Pre-Pandemic Rates; Ampligen Shows Strong Antiviral Effect Beneficial For ME/CFS And Post-COVID Fatigue; 531 Of 4,515 Participants Affected

Comments

Near Intelligence Inc Warrants (06/01/2025)

Near Intelligence Inc Warrants (06/01/2025) (NIRWQ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga